Vendor, Berlin, DEU
Myelo Therapeutics GMBH
UEI G1LNCHNLYXF6, CAGE DP990
1 award and $0 obligated between February 28, 2024 and January 16, 2025, 100% under full and open competition, against 7.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93020C00005Definitive Contract, February 28, 2024, Full and Open Competition, 7 offers | National Institutes of Health NiaidNational Institutes of Health | Development of Myelo001 as an Orally Applied Medical Countermeasure for the Treatment of Hematopoietic Acute Radiation SyndromeNAICS 541714, PSC AN12 | $0 |
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 5 across 1 awards